An Exosome Protein Sets the Stage for a Cancer Biomarker

Many cancers upregulate an amino acid transporter to fuel their growth, making this protein a promising tool in tumor detection and therapy.

Shelby Bradford, PhD
| 4 min read
3D illustration of a blue cancer cell secreting tiny blue exosomes. On the right and left, two purple immune cells flank the cancer cell.

A protein on cancer cell exosomes could lend itself to both diagnostic and therapeutic potential.

©istock, Meletios Verras

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Cellular communication is vital for passing information to neighboring cells. One key messenger in this process is an exosome, a nanosized particle that buds off from a progenitor cell, carrying molecular cargo. Because these small, cellular vehicles carry contents from their parent cells, exosomes can serve as snapshots for a given population of cells, including tumors.

“If you can sample a vesicle, or any entity, from blood, it gives you a huge advantage, being a low or minimally invasive strategy to monitor cancer or detect cancer,” said David Greening, a biologist who studies extracellular vesicles like exosomes at La Trobe University.

One strategy to improve the use of exosomes as cancer biomarkers is to identify surface proteins on these vesicles that reflect their originating tumor.1 L-type amino acid transporter 1 (LAT1), a surface protein that shuttles large amino acids into the cell, is predominantly associated with cancerous cells and correlates with tumor severity.2,3 These characteristics made the protein an attractive target for therapeutic intervention, with one LAT1 inhibitor currently undergoing clinical trials.4

Photograph of Ryuichi Ohgaki, a pharmacologist at Osaka University. He’s standing beside a leafless tree wearing a collared shirt and brown vest. He has short dark hair and round glasses.
Ryuichi Ohgaki and his team study LAT1 in the context of cancer. Now, they are interested in its potential as a druggable biomarker.
Ryuichi Ohgaki

In a study published in Scientific Reports, researchers demonstrated the potential of LAT1 on exosomes from pancreatic and other cancer cell lines as a biomarker. 5 “[Now] we can detect and treat cancer using the same target,” said Ryuichi Ohgaki, a pharmacologist at Osaka University and study coauthor.

Ohgaki and his team studied the role of LAT1 in driving cancer progression for years. Inspired by previous work that measured cancer-associated proteins on exosomes, the group set out to investigate the correlation between LAT1 expression on exosomes and their originating cancer cells.

To explore this relationship, the team used ultracentrifugation to isolate these particles from human pancreatic, cervical, and bile duct tumor cell lines. In most of the tested cell lines, LAT1 expression on exosomes correlated with LAT1 expression on cell membranes.

To study exosomes in vivo, the team introduced pancreatic cancer cells into the peritoneal cavity of mice. One month later, they used immunohistochemistry to measure LAT1 expression in tumor tissue and adjacent nontumor cells, finding the protein exclusively in the tumor tissue. When they isolated exosomes from the peritoneal cavities of tumor-bearing and control mice, they detected greater LAT1 expression on the vesicles from the mice with tumors.

According to Ohgaki, the advantage of pursuing LAT1 as a biomarker is its dual potential as both a diagnostic and a therapeutic target. Toward this goal, he and his team are exploring ways to optimize the use of exosomal LAT1. One approach involves developing an antibody that can detect the surface-exposed portion of LAT1. Although LAT1 is a surface marker, the team used an antibody that recognizes an intra-exosomal region of the protein, requiring them to lyse the exosomes to confirm LAT1 expression.

Transmission electron microscopy image of a cancer-cell derived exosome. The exosome appears as a light gray circular object, and the LAT1 appears as block dots on the surface of the exosome.
LAT1 on cancer-cell derived exosomes could serve as a diagnostic marker for cancer.
Ryuichi Ohgaki

“If we can make such an antibody, we can directly detect LAT1 on liquid biopsy, like blood or plasma,” Ohgaki said. Greening, who wasn’t involved in the study, echoed the importance of targeting the surface portion of LAT1 with an antibody to improve its potential as a biomarker.

Additionally, establishing more sensitive means to identify LAT1 on exosomes could also improve its detection at lower volumes of exosomes, like in the blood and during the early stages of cancer progression. Since the in vitro studies compared exosomes from cancer cells, Greening said that he is also interested in seeing how well LAT1 discriminates between exosomes from healthy and diseased cells.

“This is quite preliminary in discovery, in terms of can we identify a marker in an extracellular vesicle that may indicate the onset of pancreatic cancer,” said Greening. However, because there are limited diagnostic and treatment options for pancreatic cancer, he added that identifying early markers of the disease is needed. “There’s huge potential here to find something that can help many patients.”

Keywords

Meet the Author

  • Shelby Bradford, PhD

    Shelby Bradford, PhD

    Shelby is an assistant editor for The Scientist. She earned her PhD from West Virginia University in immunology and microbiology and completed an AAAS Mass Media fellowship.
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio